Pharsight

1. List of Vizimpro drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7772243	PFIZER	4-phenylamino-quinazolin-6-yl-amides	Aug, 2028 (5 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8623883	PFIZER	4-phenylamino-quinazolin-6-yl-amides	May, 2025 (2 years from now)
US10603314	PFIZER	Method for treating gefitinib resistant cancer	Feb, 2026 (3 years from now)
US10596162	PFIZER	Method for treating gefitinib resistant cancer	Feb, 2026 (3 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Sep 27, 2025
New Chemical Entity Exclusivity (NCE)	Sep 27, 2023

NCE-1 date: September, 2022

Market Authorisation Date: 27 September, 2018

Treatment: First-line treatment of metastatic non small-cell lung cancer (nsclc) with egfr exon 19 deletions or exon 21 (l858r) substitution mutations as detected by an fda-approved test; Administering daily a unit dosage of an irreversible egfr inhibitor covalently binding as claimed for 1st line treatment of gefitinib of erlotinib resistant metastatic nsclc with egfr exon 19 deletion or exon 21 l858r substitution; Administering daily a unit dosage of an irreversible egfr inhibitor covalently binding as claimed for 1st line treatment of gefitinib or erlotinib resistant metastatic nsclc with egfr exon 19 deletion or exon 21 l858r substitution with t790m mutation

Dosage: TABLET;ORAL